Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study

Keyphrases

• Adverse Events 100%
• Thyroid Eye Disease 100%
• Teprotumumab 100%
• Related Adverse Events 100%
• Diplopia 16%
• Proptosis 16%
• Event Duration 11%
• Clinical Activity Score 11%
• Score Reduction 11%
• Inflammatory Bowel Disease 5%
• Hyperglycemia 5%
• Metabolic 5%
• Hearing Impairment 5%
• Activity Level 5%
• Gastrointestinal Tract 5%
• Treating Physicians 5%
• Disease Flare 5%
• Event Risk 5%
• Retrospective Observational Study 5%
• Muscle Spasm 5%
• Primary Outcome Measure 5%
• Most Common Form 5%
• Serious Adverse Events 5%
• Nervous System 5%
• Financial Disclosure 5%
• Treatment Cessation 5%
• Reproductive System 5%
• Footnotes 5%
• Event Severity 5%
• Stage Level 5%
• Event Metrics 5%
• Tertiary Care Centers 5%
• Secondary Outcome Measures 5%
• Event Onset 5%

Medicine and Dentistry

• Adverse Event 100%
• Endocrine Ophthalmopathy 100%
• Teprotumumab 100%
• Infusion 15%
• Exophthalmos 15%
• Diplopia 15%
• Disease Exacerbation 5%
• Inflammatory Bowel Disease 5%
• Hyperglycemia 5%
• Nervous System 5%
• Reproductive System 5%
• Muscle Spasm 5%
• Hearing Impairment 5%
• Cohort Studies 5%
• Musculoskeletal System 5%

Nursing and Health Professions

• Endocrine Ophthalmopathy 100%
• Adverse Event 100%
• Teprotumumab 100%
• Infusion 15%
• Exophthalmos 15%
• Diplopia 15%
• Patient Monitor 5%
• Cohort Analysis 5%
• Hearing Impairment 5%
• Inflammatory Bowel Disease 5%
• Disease Exacerbation 5%
• Muscle Spasm 5%
• Hyperglycemia 5%
• Musculoskeletal System 5%